Last Price$228.1(1.8%)
Market Cap$16.9B
LTM Gross margin
34.6%
5Y avg
37.5%
Medical - Instruments & Supplies industry
median
48.7%
Stock quality & Intrinsic value
6/10
(0.3%) overvalued
West Pharmaceutical Services, Inc. Gross margin
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 27.5% | 28.7% | 28.6% | 28.8% | 28.8% | 28.8% | 28.5% | 30.6% | 31.8% | 31.5% | 32.6% | 33.2% | 32.1% | 31.8% | 32.9% | 35.8% | 41.5% | 39.4% | 38.3% | 34.5% |
Overvalued or undervalued?
Check the intrinsic value for WST
and see if it's the right time to invest.
West Pharmaceutical Services, Inc. (WST) Gross margin comparison analysis
General
LTM Gross margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
West Pharmaceutical Services, Inc.WST
34.6%
(1.9%)
(15.5%)
17.0%
Median Peer Set
55.9%
3.4%
23.0%
10.2%
Intuitive Surgical, Inc.ISRG
67.5%
17.2%
27.7%
27.8%
The Cooper Companies, Inc.COO
62.8%
8.4%
32.2%
10.1%
Becton, Dickinson and CompanyBDX
59.4%
4.2%
18.3%
8.4%
ResMed Inc.RMD
57.9%
10.9%
13.4%
21.8%
Hologic, Inc.HOLX
56.2%
(0.0%)
81.1%
19.6%
Alcon Inc.ALC
55.6%
8.5%
182.9%
10.3%
AptarGroup, Inc.ATR
48.7%
2.7%
30.2%
10.5%
Masimo CorporationMASI
48.0%
0.6%
(42.5%)
4.0%
Repligen CorporationRGEN
46.9%
(21.1%)
(80.9%)
5.6%
Baxter International Inc.BAX
37.1%
(69.5%)
(100.0%)
(6.9%)
WST key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 699.7 29.2% | 913.3 30.5% | 1,020.1 11.7% | 1,051.1 3.0% | 1,055.7 0.4% | 1,104.7 4.6% | 1,192.3 7.9% | 1,266.4 6.2% | 1,368.4 8.1% | 1,421.4 3.9% | 1,399.8 (1.5%) | 1,509.1 7.8% | 1,599.1 6.0% | 1,717.4 7.4% | 1,839.9 7.1% | 2,146.9 16.7% | 2,831.6 31.9% | 2,886.9 2.0% | 2,949.8 2.2% | 2,893.2 (1.9%) |
| Cost of Goods Sold (COGS) | 507.1 | 651.5 | 728.3 | 748.5 | 752.1 | 786.6 | 853.0 | 878.7 | 933.7 | 973.6 | 944.0 | 1,008.0 | 1,086.5 | 1,172.0 | 1,234.2 | 1,379.1 | 1,655.8 | 1,750.7 | 1,820.6 | 1,894.7 |
% margin | 192.6 27.5% | 261.8 28.7% | 291.8 28.6% | 302.6 28.8% | 303.6 28.8% | 318.1 28.8% | 339.3 28.5% | 387.7 30.6% | 434.7 31.8% | 447.8 31.5% | 455.8 32.6% | 501.1 33.2% | 512.6 32.1% | 545.4 31.8% | 605.7 32.9% | 767.8 35.8% | 1,175.8 41.5% | 1,136.2 39.4% | 1,129.2 38.3% | 998.5 34.5% |
| Operating Expenses | 121.7 | 160.8 | 168.6 | 191.9 | 197.6 | 213.3 | 221.7 | 251.3 | 272.8 | 266.0 | 267.1 | 276.6 | 281.7 | 303.2 | 311.6 | 360.9 | 423.5 | 402.2 | 454.0 | 428.6 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 16.1 | 18.7 | 19.9 | 23.9 | 29.1 | 33.2 | 37.9 | 37.3 | 34.1 | 36.8 | 39.1 | 40.3 | 38.9 | 46.9 | 52.8 | 58.5 | 68.4 | 69.1 |
| Selling, General & Administrative Expenses (SG&A) | 120.3 | 155.9 | 152.5 | 159.3 | 177.7 | 187.7 | 191.1 | 218.1 | 234.9 | 228.7 | 233.0 | 239.8 | 242.6 | 262.9 | 272.7 | 302.0 | 362.8 | 316.9 | 353.4 | 338.5 |
% margin | 72.2 10.3% | 101.0 11.1% | 94.9 9.3% | 124.1 11.8% | 97.5 9.2% | 90.7 8.2% | 109.6 9.2% | 135.1 10.7% | 162.4 11.9% | 182.0 12.8% | 128.6 9.2% | 196.8 13.0% | 228.9 14.3% | 240.3 14.0% | 296.6 16.1% | 406.9 19.0% | 752.3 26.6% | 734.0 25.4% | 676.0 22.9% | 569.9 19.7% |
| Interest Income | 0.0 | 0.0 | 6.0 | 1.4 | 0.8 | 0.6 | 1.3 | 1.8 | 1.9 | 3.5 | 1.6 | 1.1 | 1.3 | 2.1 | 3.8 | 1.4 | 1.0 | 5.1 | 28.0 | 19.6 |
| Interest Expense | 0.0 | 0.0 | 14.5 | 16.0 | 14.4 | 16.8 | 18.2 | 14.9 | 15.1 | 13.0 | 12.5 | 7.0 | 6.5 | 6.3 | 4.7 | 6.8 | 7.2 | 7.9 | 9.0 | 3.0 |
| Pre-tax Income | 45.2 | 84.5 | 86.4 | 109.5 | 83.1 | 74.5 | 92.7 | 108.6 | 147.1 | 169.0 | 116.1 | 189.8 | 222.4 | 240.7 | 291.8 | 401.3 | 748.9 | 679.9 | 698.0 | 585.5 |
% effective tax rate | (0.4) (0.9%) | 24.6 29.1% | 17.2 19.9% | 23.7 21.6% | 13.5 16.2% | 13.6 18.3% | 23.5 25.4% | 32.7 30.1% | 40.2 27.3% | 47.2 27.9% | 26.3 22.7% | 54.4 28.7% | 80.9 36.4% | 41.4 17.2% | 59.0 20.2% | 72.5 18.1% | 107.2 14.3% | 114.7 16.9% | 122.3 17.5% | 107.5 18.4% |
% margin | 45.6 6.5% | 67.1 7.3% | 70.7 6.9% | 86.0 8.2% | 72.6 6.9% | 65.3 5.9% | 75.5 6.3% | 80.7 6.4% | 112.3 8.2% | 127.1 8.9% | 95.6 6.8% | 143.6 9.5% | 150.7 9.4% | 206.9 12.0% | 241.7 13.1% | 346.2 16.1% | 661.8 23.4% | 585.9 20.3% | 593.4 20.1% | 492.7 17.0% |
| EPS | 0.75 | 1.05 | 1.08 | 1.33 | 1.11 | 0.98 | 1.12 | 1.19 | 1.61 | 1.79 | 1.33 | 1.96 | 2.04 | 2.80 | 3.27 | 4.68 | 8.90 | 7.88 | 7.99 | 6.75 |
| Diluted EPS | 0.71 | 1.00 | 1.02 | 1.25 | 1.06 | 0.95 | 1.08 | 1.15 | 1.57 | 1.75 | 1.30 | 1.91 | 1.99 | 2.74 | 3.21 | 4.57 | 8.67 | 7.73 | 7.88 | 6.69 |
% margin | 122.9 17.6% | 149.9 16.4% | 157.5 15.4% | 186.1 17.7% | 166.4 15.8% | 161.3 14.6% | 183.4 15.4% | 200.0 15.8% | 249.0 18.2% | 273.3 19.2% | 220.0 15.7% | 319.6 21.2% | 335.9 21.0% | 355.3 20.7% | 399.4 21.7% | 531.7 24.8% | 895.2 31.6% | 887.9 30.8% | 844.1 28.6% | 743.9 25.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is West Pharmaceutical Services, Inc.'s Gross margin?
As of today, Microsoft Corp's last 12-month Gross margin is 34.6%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Gross margin for West Pharmaceutical Services, Inc. have been 38.6% over the past three years, and 39.4% over the past five years.
2) Is West Pharmaceutical Services, Inc.'s Gross margin Good?
As of today, West Pharmaceutical Services, Inc.'s Gross margin is 34.6%, which is lower than industry median of 48.7%. It indicates that West Pharmaceutical Services, Inc.'s Gross margin is Bad.